ALN-PNP Investigational PNPLA3-silencing RNAi therapy licensed to Regeneron, in Phase 2 development for fatty liver disease associated with metabolic dysfunction.
Visit productCosigns Received
Be the first Cosign
Put your name behind ALN-PNP.
Add it to your Products I use list and share why you use it.